Inhibition of CD49d-mediated interactions could be envisioned as a novel therapeutic strategy for improving disease progression in DMD patients, by decreasing the immune response, in conjunction with other gene therapy approaches such as exon skipping or gene replacement, which in some cases triggers dystrophin-specific immune response [29–31]. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.